Bluejay Diagnostics, Inc.
BJDX Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$0.59
KIRA · Stoqly’s AI analyst, in plain words
- Bluejay Diagnostics, Inc. lost $6.8M in fiscal 2025.
- Free cash flow was −$6.2M in fiscal 2025, — of revenue.
Market cap
$1.2M
P/E
0.8x
Revenue
—
Net income
−$6.8M
Free cash flow
−$6.2M
Operating margin
—
Bluejay Diagnostics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$6.8M
No. It lost money last year.
How is the share priced?
0.8x
One share costs 0.8 times its yearly profit per share.
What Bluejay Diagnostics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 6, 2026
- Legal name
- Bluejay Diagnostics, Inc.
- CIK
- 0001704287
Bluejay Diagnostics, Inc. · BJDX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | −$0.4M | $0.2M | — | — | — |
| Net interest income | −$0.4M | — | — | — | — |
| Gross margin | — | 19.6% | — | — | — |
| Operating margin | 879.0% | −3,742.1% | — | — | — |
| Net income | −$3.5M | −$9.3M | −$10.0M | −$7.7M | −$6.8M |
| Net margin | 949.2% | −3,733.7% | — | — | — |
| Diluted EPS | −$0.41 | −$9.22 | −$3,631.48 | −$456.75 | −$15.25 |
| Cash | |||||
| Cash from operations | −$4.4M | −$7.7M | −$8.3M | −$7.8M | −$6.1M |
| Capital expenditure | $0.0M | $1.2M | $0.7M | $0.3M | $0.2M |
| Free cash flow | −$4.4M | −$8.9M | −$9.0M | −$8.1M | −$6.2M |
| FCF margin | 1,194.7% | −3,590.7% | — | — | — |
| Share count change | 170.8% | −88.2% | −99.7% | 1,596.3% | 880.3% |
| Debt and strength | |||||
| Cash and short-term investments | $19.0M | $10.1M | $2.2M | $4.3M | $5.2M |
| Shareholders' equity | $20.4M | $11.5M | $2.9M | $5.7M | $6.0M |
| Current ratio | 32.4x | 7.2x | 1.8x | 6.0x | 4.9x |
| Interest coverage | −504.7x | — | — | −8.7x | −8,691.3x |
| Returns and quality | |||||
| Return on equity | −43.1% | −58.2% | −137.9% | −179.0% | −117.0% |
| Return on tangible equity | −17.1% | −80.6% | −343.9% | −365.5% | −114.6% |
| Piotroski F-score | — | 3 | — | — | — |
| Altman Z'' | 37.6 | 2.3 | −28.8 | −13.7 | −16.1 |
Insiders bought, 12 months
$0.2M
6 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Bluejay Diagnostics, Inc. · BJDX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.59 a share, the company is worth $1.2M: 0.8 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001704287). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.